drugset / Trial / NCT02815592

Trial of BMS-986012 in Combination With Platinum and Etoposide

NCT02815592

Phase 1 Completed 12 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Timeline

Start
2016-11-28
Primary completion
2019-12-15
Completion
2024-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Cisplatin Other / unclassified
Subject atigotatug Monoclonal antibody
Background Etoposide Small molecule